ANI PHARMACEUTICALS, INC Gain (Loss) on Repurchase of Debt Instrument
ANI PHARMACEUTICALS, INC (ANIP) reported Gain (Loss) on Repurchase of Debt Instrument of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnRepurchaseOfDebtInstrument · last filed 2021-03-11
- ANI PHARMACEUTICALS, INC gain (loss) on repurchase of debt instrument for fiscal 2020 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) on repurchase of debt instrument for fiscal 2019 was $0.00.
- ANI PHARMACEUTICALS, INC gain (loss) on repurchase of debt instrument for fiscal 2018 was -$468.00K.
- ANI PHARMACEUTICALS, INC gain (loss) on repurchase of debt instrument for fiscal 2017 was $0.00.
| Period end | Gain (Loss) on Repurchase of Debt Instrument 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-11 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
| 2018-12-31 | -$468.00K 10-K · filed 2021-03-11 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |